FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

993 letters match. Newest first.

  1. American Pharma Mfg. Inc.

    FDA warns American Pharma Mfg. of serious dietary supplement manufacturing violations at its Ontario, CA facility.

    High risk
  2. Wellmill, LLC dba Vitamix Laboratories

    FDA warned Vitamix Laboratories that its juice-with-probiotics products were adulterated because it lacked required hazard controls and a 5-log pathogen reduction.

    High risk
  3. Middlefield Original Cheese Cooperative

    FDA warns Middlefield Original Cheese Cooperative about Listeria and insanitary conditions in its ready-to-eat cheese.

    High risk
  4. VeganicSKN Limited

    FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.

    High risk
  5. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium
  6. Kellin Chemicals Co., Ltd. - Zhangjiagang

    Kellin Chemicals' API site refused FDA inspection, so FDA calls its drugs adulterated.

    High risk
  7. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  8. NexCell Scientific Inc

    NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.

    High risk
  9. kdc/one Chatsworth, Inc.

    FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.

    High risk
  10. Binh Minh Tofu

    FDA warned Binh Minh Tofu that its ready-to-eat tofu was adulterated after a March 2026 inspection found unsafe cooling, sanitation and hygiene failures.

    High risk
  11. Specialty Health Products CO, LLC

    Specialty Health Products was cited for quality-system, unapproved marketing, and listing violations for its Hydro-San and Aqua Cleanse colonic irrigation devices.

    High risk
  12. Bausch & Lomb Inc.

    FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.

    High risk
  13. Happy Farm Botanicals, Inc.

    Happy Farm Botanicals, an OTC drug maker in Hyattsville, MD, cited for skipping ingredient identity tests and stability testing, repeat violations.

    High risk
  14. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  15. Fresenius Medical Care AG & Co. KGaA

    Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.

    High risk
  16. Reliance Life Sciences Private Limited

    FDA warned India's Reliance Life Sciences over falsified microbiology records and aseptic failures in sterile drug production, prompting a recall.

    High risk
  17. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  18. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  19. R3 Medical Companies

    FDA cites R3 Medical affiliates for selling unapproved umbilical cord and exosome biologics without licenses and with serious manufacturing violations.

    High risk
  20. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk
  21. Eugia Pharma Specialities Limited

    FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.

    High risk
  22. K.C. Pharmaceuticals, Inc.

    FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.

    High risk
  23. Auriga Research Pvt. Ltd.

    Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.

    High risk
  24. Safrel Pharmaceuticals LLC

    FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.

    High risk
  25. Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.

    Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.

    High risk
  26. Nipro Renal Solutions USA, Corporation

    Nipro Renal Solutions USA released hemodialysis dialysate lots with out-of-spec endotoxin (bacterial toxin) and had widespread quality-system failures, FDA says.

    High risk
  27. Waves and Wine, Inc.

    FDA warns Waves and Wine, a California raw pet food maker, over Listeria in its beef pet foods and inadequate food safety controls.

    High risk
  28. FairyGene, Inc.

    FDA cites FairyGene, a Bristol, PA contract manufacturer, for unsanitary facility and cleaning practices and for selling five unapproved drug balms.

    High risk
  29. Lico Industries, LLC., d.b.a. American Towelette Company

    FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.

    High risk
  30. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  31. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk
  32. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk
  33. ABS Corporation

    ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.

    High risk
  34. Koven Technologies, Inc.

    FDA warns Koven Technologies that its Bidop 3 Doppler was labeled for fetal use without clearance and had quality system violations.

    High risk
  35. AHC Products, Inc.

    AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.

    High risk
  36. Linemaster Switch Corporation

    Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.

    High risk
  37. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk
  38. Almon Healthcare Private Limited

    Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.

    High risk
  39. BioMylz Pvt. Ltd.

    FDA found destroyed records, inadequate process and cleaning validation, missing microbial testing, and incomplete drug listings at BioMylz, an Indian OTC drug manufacturer.

    High risk
  40. Shimoga Chemicals

    FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.

    High risk
  41. Mineral BioSciences, LLC

    Mineral BioSciences’ Totala and Ionicell supplements were flagged as unapproved new drugs and misbranded, with manufacturing violations.

    High risk
  42. Fareva Amboise

    FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.

    High risk
  43. Spa De Soleil, Inc.

    FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.

    High risk
  44. International Medication Systems Limited

    FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.

    High risk
  45. Nutratech, LLC

    FDA cited Nutratech, LLC for manufacturing violations and an undeclared allergen in dietary supplements.

    High risk
  46. AF Import & Wholesale Co

    FDA warned Houston seafood importer AF Import & Wholesale for missing written verification that its imported fish was processed safely.

    High risk
  47. ZIIP, Inc.

    FDA warns ZIIP over quality-system violations and unapproved marketing of HALO 2.0, DOT, and gels.

    High risk
  48. Excelvision - Fareva

    FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.

    High risk
  49. Wizcure Pharmaa Private Limited

    FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.

    High risk
  50. Genzyme Ireland Limited

    Genzyme Ireland's Waterford biologics plant cited for quality unit and data integrity failures across two licensed products.

    High risk